Phase 2 Study of 500 mg BID NTZ on Top of Standard of Care in Patients With Acute Decompensation of Liver Cirrhosis at High Risk of Progression to Acute-on-Chronic Liver Failure or Established Acute-on-Chronic Liver Failure
18h agoen
From the article
Conditions : Acute Decompensation of Liver Cirrhosis; Established Acute-on-Chronic Liver Failure Interventions : Drug: NTZ 500mg BID on top of SOC Sponsors : Genfit Not yet recruiting
Continue reading on clinicaltrials.govYou might also wanna read
Acute Hepatic Porphyria: Expert-Led Case-Based Education on Early Diagnosis and Treatment
This article presents a case-based educational program on Acute Hepatic Porphyria (AHP), moderated by the United Porphyrias Association pres
mdsc.pe·9d agoScipher picks up Chemomab’s liver disease drug, Nasdaq listing in all-stock merger
Fierce Biotech·1d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.